Stock Analiz

Virax Biolabs Group Ltd VRAX

Biotechnology: In Vitro & In Vivo Diagnostic Substances · IPO 2022 · data as of November 13, 2026

$0.61Market cap $823939
Open the interactive analysis →

Virax Biolabs Group Ltd (VRAX) is a healthcare company listed in the US with a market value of about $823939. In fiscal year 2026 it had revenue of $12423 and net income of -$5M, a net margin of -40439.1%.

Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -84%.

About Virax Biolabs Group

Virax Biolabs Group is listed in the US and classified in biotechnology: in vitro & in vivo diagnostic substances, IPO year 2022. Revenue went from $123820 in 2021 to $12423 in 2026, a decline of about 36.9% a year. It was profitable in 0 of the last 6 years in our data. Its share count fell by 70% over three years (buybacks).

Score: 1.6 / 5

Value0/5
Future growth3/5
Track record0/5
Financial health4/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets
  • Share count down over 3 years (buybacks)

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S66.3
P/B0.1
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-592.0%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-96.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-41079.5%
ROIC (5-yr avg.)-83.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal year202620252024202320222021
Revenue$12423$6331$156419$8561$0$123820
Net income-$5M-$6M-$7M-$5M-$2M-$650984
Free cash flow-$5M-$5M-$7M———
EPS (diluted)$-12.64$-4.51$-5.01$-4.06$-1.27$-0.48
Net margin-40439.1%-95739.2%-4304.8%-63748.3%—-525.8%
ROIC—-105.8%-95.6%-49.6%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Virax Biolabs Group pay a dividend?

Not currently.

Is Virax Biolabs Group a good stock to buy?

We do not give buy or sell advice. Virax Biolabs Group scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.